LD-2 disclosure · 1st Quarter - Report
A.P. GOLDSHIELD LLC
Client
- Description
- anti microbial distribution company
- Location
- New York · United States of America
Registrant
- Description
- self employed, lobby congress and executive branch on behalf of clients
- Location
- Rehoboth Beach, Delaware, United States of America
Lobbying activities
3 issuesHealth Issues
had discussions with officials of the Environmental Protection Agency, regarding textile and disinfecting protocols under consideration by the Agency; and proposal to test client products under modified EPA Interim Guidance rules. Contacts with Members of Congress staff during this period only to send them copy of study of Goldshield performed by Oak Ridge National Laboratory. Discussion with official at Northern California VAH, Dr. John Johnson and Ms. Joyce Ullery, about possible collaboration on demonstration project at Martinez VAH in California. Had periodic contact with research team at Department of Energy Oak Ridge National Laboratory about study they were conducting on treatment of new medical mask material and other textiles, with Goldshield antimicrobial product. Brief e mail contact with NASA Jet Propulsion Lab researcher to ascertain status of their study of Goldshield in International Space Station. No other lobbying activities during this period.
LobbyistsROBERT E. MILLS
TargetedSENATE · Energy, Dept of · Veterans Affairs, Dept of (VA) · Environmental Protection Agency (EPA) · Natl Aeronautics & Space Administration (NASA)
Agriculture
No discussions with the Department of Agriculture or Members of Congress on agriculture issues during this period.
LobbyistsROBERT E. MILLS
Environment/Superfund
Had discussions with officials of the Environmental Protection agency during this period regarding cleaning and disinfecting and textile protocols under consideration by the Agency; and pursuit of label claims following proposed test of client products against EPA Interim Guidance. Discussed possible test of Goldshield under modified EPA Interim Guidance on antiviral residual protection.
